前の章|次の章

上昇したFBXL6は野生型KRASおよび変異KRASG12Dの両方を活性化し、マウスにおいてERK/mTOR/PRELID2/ROS軸を介してHCC腫瘍形成を促進する

  • role： First author第一作者
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Hao-Jun Xiong1,  
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Hong-Qiang Yu1,  
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Jie Zhang1,  
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Lei Fang1,  
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Di Wu1,  
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

Xiao-Tong Lin1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China

  • Email：cmxie@tmmu.edu.cn
  • Introduction：*cmxie@tmmu.edu.cn
Chuan-Ming Xie1*

サマリー

Background:Kirsten rat sarcoma (KRAS) and mutant KRASG12D have been implicated in human cancers, but it remains unclear whether their activation requires ubiquitination. This study aimed to investigate whether and how F-box and leucine-rich repeat 6 (FBXL6) regulates KRAS and KRASG12D activity in hepatocellular carcinoma (HCC).Methods:We constructed transgenic mouse strains LC (LSL-Fbxl6KI/+; Alb-Cre, n=13), KC (LSL-KrasG12D/+; Alb-Cre, n=10) and KLC (LSL-KrasG12D/+; LSL-Fbxl6KI/+; Alb-Cre, n=12) mice, and then monitored HCC for 320 d. Multiomics approaches and pharmacological inhibitors were used to determine oncogenic signaling in the context of elevated FBXL6 and KRAS activation. Co-immunoprecipitation (Co-IP), Western blotting, ubiquitination assay, and RAS activity detection assay were employed to investigate the underlying molecular mechanism by which FBXL6 activates KRAS. The pathological relevance of the FBXL6/KRAS/extracellular signal-regulated kinase (ERK)/mammalian target of rapamycin (mTOR)/proteins of relevant evolutionary and lymphoid interest domain 2 (PRELID2) axis was evaluated in 129 paired samples from HCC patients.Results:FBXL6 is highly expressed in HCC as well as other human cancers (P<0.001). Interestingly, FBXL6 drives HCC in transgenic mice. Mechanistically, elevated FBXL6 promotes the polyubiquitination of both wild-type KRAS and KRASG12D at lysine 128, leading to the activation of both KRAS and KRASG12D and promoting their binding to the serine/threonine-protein kinase RAF, which is followed by the activation of mitogen-activated protein kinase kinase (MEK)/ERK/mTOR signaling. The oncogenic activity of the MEK/ERK/mTOR axis relies on PRELID2, which induces reactive oxygen species (ROS) generation. Furthermore, hepatic FBXL6 upregulation facilitates KRASG12D to induce more severe hepatocarcinogenesis and lung metastasis via the MEK/ERK/mTOR/PRELID2/ROS axis. Dual inhibition of MEK and mTOR effectively suppresses tumor growth and metastasis in this subtype of cancer in vivo. In clinical samples, FBXL6 expression positively correlates with p-ERK (χ2=85.067, P<0.001), p-mTOR (χ2=66.919, P<0.001) and PRELID2 (χ2=20.891, P<0.001). The Kaplan-Meier survival analyses suggested that HCC patients with high FBXL6/p-ERK levels predicted worse overall survival (log-rank P<0.001).Conclusions:FBXL6 activates KRAS or KRASG12D via ubiquitination at the site K128, leading to activation of the ERK/mTOR/PRELID2/ROS axis and tumorigenesis. Dual inhibition of MEK and mTOR effectively protects against FBXL6- and KRASG12D-induced tumorigenesis, providing a potential therapeutic strategy to treat this aggressive subtype of liver cancer.

キーワード

Ubiquitination;Kirsten rat sarcoma (KRAS);F-box and leucine-rich repeat 6 (FBXL6);PRELID2;Reactive oxygen species;Extracellular signal-regulated kinase (ERK);Mammalian target of rapamycin

References

  1. 1..
    Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.
  2. 2..
    Gu L, Zhu Y, Lin X, Lu B, Zhou X, Zhou F, et al. The IKKβ-USP30-ACLY axis controls lipogenesis and tumorigenesis. Hepatology. 2021;73(1):160–74.
  3. 3..
    Zhu Y, Gu L, Lin X, Zhou X, Lu B, Liu C, et al. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology. 2023;77(5):1499–511.
  4. 4..
    Lu Y, Gao Y, Yang H, Hu Y, Li X. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. Mil Med Res. 2022;9(1):69.
  5. 5..
    Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17(3):139–52.
  6. 6..
    Nault JC, Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 2015;21(8):1786–8.
  7. 7..
    Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;25(2):301–11.
  8. 8..
    Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327-41.e23.
  9. 9..
    Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–6.
  10. 10..
    Jeong WJ, Yoon J, Park JC, Lee SH, Lee SH, Kaduwal S, et al. Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis. Sci Signal. 2012;5(219):ra30.
  11. 11..
    Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, et al. Wild-type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL-8 secretion via JAK2 activation. Cell Rep. 2015;12(3):511–24.
  12. 12..
    Calaf GM, Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016;11(6):3637–42.
  13. 13..
    Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and JAK/STAT pathways in human HCC. Gastroenterology. 2006;130(4):1117–28.
  14. 14..
    Chen L, Shi Y, Jiang CY, Wei LX, Wang YL, Dai GH. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2011;37(6):513–20.
  15. 15..
    Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006;25(45):6056–66.
  16. 16..
    Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2018;67(7):1328–41.
  17. 17..
    Jeong WJ, Park JC, Kim WS, Ro EJ, Jeon SH, Lee SK, et al. WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nat Commun. 2019;10(1):295.
  18. 18..
    Roukens MG, Alloul-Ramdhani M, Moghadasi S, Op Den Brouw M, Baker DA. Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination. Mol Cell Biol. 2008;28(13):4394–406.
  19. 19..
    Li Y, Cui K, Zhang Q, Li X, Lin X, Tang Y, et al. FBXL6 degrades phosphorylated p53 to promote tumor growth. Cell Death Differ. 2021;28(7):2112–25.
  20. 20..
    Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, et al. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Commun Signal. 2020;18(1):100.
  21. 21..
    Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, et al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 2011;4(163):ra13.
  22. 22..
    Steklov M, Pandolfi S, Baietti MF, Batiuk A, Carai P, Najm P, et al. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science. 2018;362(6419):1177–82.
  23. 23..
    Baker R, Wilkerson EM, Sumita K, Isom DG, Sasaki AT, Dohlman HG, et al. Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination. J Biol Chem. 2013;288(52):36856–62.
  24. 24..
    Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.
  25. 25..
    Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
  26. 26..
    Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–32.
  27. 27..
    Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, et al. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut. 2016;65(4):647–57.
  28. 28..
    Moore AR, Rosenberg SC, Mccormick F, Malek S. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov. 2020;19(8):533–52.
  29. 29..
    Ming M, Ying M, Ling M. miRNA-125a-5p inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting TP53 regulated inhibitor of apoptosis 1 and Bcl-2-like-2 protein. Exp Ther Med. 2019;18(2):1196–202.
  30. 30..
    Potting C, Tatsuta T, König T, Haag M, Wai T, Aaltonen MJ, et al. TRIAP1/PRELI complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid. Cell Metab. 2013;18(2):287–95.
  31. 31..
    Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–25.
  32. 32..
    Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285(5430):1028–32.
  33. 33..
    Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79–94.
  34. 34..
    Huse M. The T-cell-receptor signaling network. J Cell Sci. 2009;122(Pt 9):1269–73.
  35. 35..
    Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013;3(5):548–63.
  36. 36..
    Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33.
  37. 37..
    Yu Y, Yao W, Wang T, Xue W, Meng Y, Cai L, et al. FBXL6 depletion restrains clear cell renal cell carcinoma progression. Transl Oncol. 2022;26:101550.
  38. 38..
    Meng L, Hu YT, Xu AM. F-box and leucine-rich repeat 6 promotes gastric cancer progression via the promotion of epithelial-mesenchymal transition. World J Gastrointest Oncol. 2023;15(3):490–503.
  39. 39..
    Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58.
  40. 40..
    Deng GH, Wu CF, Li YJ, Shi H, Zhong WC, Hong MK, et al. Caveolin-1 is critical for hepatic iron storage capacity in the development of nonalcoholic fatty liver disease. Mil Med Res. 2023;10(1):53.
  41. 41..
    Turhal NS, Savaş B, Çoşkun Ö, Bas E, Karabulut B, Nart D, et al. Prevalence of K-Ras mutations in hepatocellular carcinoma: a Turkish Oncology Group pilot study. Mol Clin Oncol. 2015;3(6):1275–9.
  42. 42..
    Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015;45(6):609–23.
  43. 43..
    Guzman-Rojas L, Sims JC, Rangel R, Guret C, Sun Y, Alcocer JM, et al. PRELI, the human homologue of the avian px19, is expressed by germinal center B lymphocytes. Int Immunol. 2000;12(5):607–12.
  44. 44..
    Miliara X, Tatsuta T, Berry JL, Rouse SL, Solak K, Chorev DS, et al. Structural determinants of lipid specificity within Ups/PRELI lipid transfer proteins. Nat Commun. 2019;10(1):1130.
  45. 45..
    Zhu Y, Zou R, Sha H, Lu Y, Zhang Y, Wu J, et al. Lipid metabolismrelated proteins of relevant evolutionary and lymphoid interest (PRELI) domain containing family proteins in cancer. Am J Transl Res. 2020;12(10):6015–26.
  46. 46..
    Liu G, Zeng X, Wu B, Zhao J, Pan Y. RNA-Seq analysis of peripheral blood mononuclear cells reveals unique transcriptional signatures associated with radiotherapy response of nasopharyngeal carcinoma and prognosis of head and neck cancer. Cancer Biol Ther. 2020;21(2):139–46.
  47. 47..
    Wang W, Ji J, Li J, Ren Q, Gu J, Zhao Y, et al. Several critical genes and microRNAs associated with the development of polycystic ovary syndrome. Ann Endocrinol. 2020;81(1):18–27.
  48. 48..
    Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2014;33(9):1181–9.
  49. 49..
    Zhang X, Zhang T, Yang K, Zhang M, Wang K. miR-486-5p suppresses prostate cancer metastasis by targeting Snail and regulating epithelialmesenchymal transition. Onco Targets Ther. 2016;9:6909–14.
  50. 50..
    Liu C, Li M, Hu Y, Shi N, Yu H, Liu H, et al. miR-486-5p attenuates tumor growth and lymphangiogenesis by targeting neuropilin-2 in colorectal carcinoma. Onco Targets Ther. 2016;9:2865–71.
  51. 51..
    Tahvanainen J, Kallonen T, Lähteenmäki H, Heiskanen KM, Westermarck J, Rao KV, et al. PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. Blood. 2009;113(6):1268–77.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website